Niagen Bioscience (NAGE) Net Income towards Common Stockholders (2010 - 2026)

Niagen Bioscience (NAGE) has 16 years of Net Income towards Common Stockholders data on file, last reported at $6.3 million in Q1 2026.

• Net Income towards Common Stockholders for Q1 2026 came in at $6.3 million, up 24.79% year-over-year; the trailing twelve-month figure through Mar 2026 was $18.6 million (up 32.13% YoY), and the FY2025 annual result was $17.4 million, up 103.3% from the prior year.
• Net Income towards Common Stockholders advanced to $6.3 million in Q1 2026 per NAGE's latest filing, from $4.1 million in the prior quarter.
• Over five years, Net Income towards Common Stockholders peaked at $7.2 million in Q4 2024 and troughed at -$7.7 million in Q1 2022.
• A 5-year average of $505588.2 and a median of -$15000.0 in 2024 frame the typical range for Net Income towards Common Stockholders.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 24160.0% in 2025 and fell as far as 42.44% in 2025.
• A 5-year view of Net Income towards Common Stockholders shows it stood at -$1.4 million in 2022, then surged by 107.89% to $114000.0 in 2023, then surged by 6197.37% to $7.2 million in 2024, then plunged by 42.44% to $4.1 million in 2025, then soared by 52.9% to $6.3 million in 2026.
• Business Quant data shows NAGE's Net Income towards Common Stockholders at $6.3 million in Q1 2026, $4.1 million in Q4 2025, and $4.6 million in Q3 2025.